We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current CLDX market cap is 2.15B. The company's latest EPS is USD -2.5300 and P/E is -15.15.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 407k | 8.48M | 967k | 267k | 1.52M |
| Operating Income | -27.7M | -21.02M | -32.47M | -33.21M | -41.24M |
| Net Income | -26.78M | -26.49M | -29.36M | -30.5M | -38.26M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 4.87M | 11.64M | 6.06M | 9.22M | 6.88M |
| Operating Income | -53.23M | -63.35M | -71.24M | -115.23M | -154.54M |
| Net Income | -50.88M | -59.78M | -70.51M | -112.33M | -141.43M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 369.23M | 352.74M | 324.52M | 299.31M | 280.26M |
| Total Liabilities | 23.81M | 26.53M | 21.78M | 21.77M | 33.54M |
| Total Equity | 345.42M | 326.2M | 302.74M | 277.54M | 246.72M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 122.93M | 235.84M | 444.65M | 352.74M | 465.63M |
| Total Liabilities | 28.91M | 26.48M | 25.18M | 26.53M | 36.46M |
| Total Equity | 94.03M | 209.36M | 419.48M | 326.2M | 429.17M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -81.97M | -103.73M | -28.57M | -55.77M | -74.76M |
| Investing | 58.73M | 89.94M | 52.57M | 53.73M | 65.38M |
| Financing | 2.68M | 4.08M | 694k | 827k | 1.08M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -46.42M | -40.4M | -60.91M | -103.73M | -107.29M |
| Investing | 17.08M | -98.22M | -216.16M | 89.94M | -105.78M |
| Financing | 16.26M | 171.23M | 272.37M | 4.08M | 218.46M |
| Market Cap | 2.15B |
| Price to Earnings Ratio | -15.15 |
| Price to Sales Ratio | 311.45 |
| Price to Cash Ratio | 61.56 |
| Price to Book Ratio | 4.99 |
| Dividend Yield | - |
| Shares Outstanding | 55.9M |
| Average Volume (1 week) | 679.82k |
| Average Volume (1 Month) | 627.27k |
| 52 Week Change | 5.51% |
| 52 Week High | 53.18 |
| 52 Week Low | 22.11 |
| Spread (Intraday) | 0.04 (0.1%) |
| Company Name | Celldex Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.celldex.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
